{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:04:11Z","timestamp":1789733051141,"version":"4.0.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ampullary cancer presents unique clinical challenges due to its rarity and diagnostic complexities. Current data addressing ampullary cancer therapy are limited. This retrospective study focused on advanced disease and explored the rational therapeutic strategies especially based on histopathological subtype, which maybe provide evidence-based guidance for this understudied malignancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled advanced ampullary cancer patients from two centers. Clinicopathological data and treatment details were collected. Treatment outcome comparisons between different chemotherapeutic regimens (gemcitabine-based vs fluorouracil-based) and different histopathologic types (Pancreaticobiliary vs Non-pancreaticobiliary) were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>71 patients with advanced ampullary cancer were enrolled. Elevated CA19\u20139 was observed in 63.4% (45\/71). Postoperative metastasis occurred in 90.1% (64\/71) patients. Histological subtyping was feasible in 43 patients, including 38 pancreaticobiliary, 4 intestinal, and 1 mixed subtype. All patients received first-line chemotherapy with objective response rate (ORR) of 19.7%, median progression-free survival (mPFS) of 9.6 months and median overall survival (mOS) of 33.2 months. Comparable efficacy between gemcitabine-based group (n=27) and fluorouracil-based group (n=44) (ORR 14.8% vs 22.7%, mPFS 6.67 months vs 11.20 months, mOS 26.70 months vs 38.90 months, p&amp;gt;0.05) were observed. Pancreatobiliary subgroup (n=38) exhibited ORR of 15.8%, median PFS of 8.33 months, and OS of 31.7 months, and 20% ORR, 9.93-month PFS, and 32.3-month OS in non-pancreatobiliary cases (n=5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Advanced ampullary cancer demonstrates aggressive behavior and poor chemotherapy responses. No formal statistical comparison was performed between histopathological subtypes due to the small sample size of the non-pancreatobiliary group. However, the number of patients with the pancreatobiliary-type was far greater than that with the non-pancreatobiliary-type. Due to the underrepresentation of non-pancreatobiliary-type cases, the predictive value of histopathological subtyping in advanced disease could not be adequately assessed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1934868","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:27:07Z","timestamp":1789730827000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological features and treatment paradigms exploration in advanced ampullary cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiayu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junliang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First People Hospital of Zhaoqing","place":["Zhaoqing, China"]},{"name":"Department of Oncology, The First Affiliated Hospital of Jinan University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medicine II, LMU University Hospital","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yize","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Surgery, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.14694\/edbook_am.2014.34.112","article-title":"Ampullary cancer: an overview","author":"Ahn","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B2","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/jso.21374","article-title":"Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program","volume":"100","author":"Albores-Saavedra","year":"2009","journal-title":"J Surg Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198902000-00008","article-title":"The gross anatomy and histology of the gallbladder, extrahepatic bile ducts, Vaterian system, and minor papilla","volume":"13","author":"Frierson","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2008.11.045","article-title":"Prospective evaluation of EUS versus CT scan for staging of ampullary carcinoma","volume":"70","author":"Artifon","year":"2009","journal-title":"Gastrointest Endosc"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2023.0034","article-title":"Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Chiorean","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i29.10144","article-title":"Trends in incidence and management of cancer of the ampulla of Vater","volume":"20","author":"Rostain","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2004.08.013","article-title":"Adjuvant chemo-radiotherapy in ampullary cancers","volume":"31","author":"Sikora","year":"2005","journal-title":"Eur J Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2023.0195","article-title":"The diagnosis and treatment of ampullary cancer","volume":"120","author":"Walter","year":"2023","journal-title":"Dtsch Arztebl Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000230","article-title":"The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater","volume":"38","author":"Ang","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.46.8868","article-title":"Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater","volume":"31","author":"Chang","year":"2013","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.172","article-title":"Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma","volume":"113","author":"Schueneman","year":"2015","journal-title":"Br J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2014.07.665","article-title":"Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma","volume":"110","author":"Okano","year":"2014","journal-title":"J Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12967-022-03473-w","article-title":"Multimodal data analysis reveals that pancreatobiliary-type ampullary adenocarcinoma resembles pancreatic adenocarcinoma and differs from cholangiocarcinoma","volume":"20","author":"Cheng","year":"2022","journal-title":"J Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary carcinoma randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"Jama"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.5009\/gnl230164","article-title":"Outcomes of palliative chemotherapy for ampulla of Vater adenocarcinoma: a multicenter cohort study","volume":"18","author":"Jang","year":"2023","journal-title":"Gut Liver"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1309\/ajcpctcuqsyi89yt","article-title":"Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications","volume":"135","author":"Kohler","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/his.12324","article-title":"Ampullary carcinoma--a separate clinical entity","volume":"64","author":"Perysinakis","year":"2014","journal-title":"Histopathology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"12676","DOI":"10.1038\/s41598-019-49179-w","article-title":"The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma","volume":"9","author":"Zimmermann","year":"2019","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0034","article-title":"Ampullary adenocancer, version 2.2025, NCCN Clinical Practice Guidelines in Oncology","author":"Tempero","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11555","article-title":"Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study","volume":"107","author":"Moekotte","year":"2020","journal-title":"Br J Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2024.3588","article-title":"Genome-derived ampullary adenocarcinoma classifier and postresection prognostication","volume":"159","author":"Ecker","year":"2024","journal-title":"JAMA Surg"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.06.019","article-title":"A randomised phase II study of oxaliplatin\/fluorouracil (mFOLFOX) versus irinotecan\/fluorouracil (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"Choi","year":"2021","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1159\/000159624","article-title":"Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer","volume":"54","author":"Oh","year":"2008","journal-title":"Chemotherapy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.231.21","article-title":"Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater","volume":"231","author":"Kim","year":"2013","journal-title":"Tohoku J Exp Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/030089161309900203","article-title":"Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater","volume":"99","author":"Sohn","year":"2013","journal-title":"Tumori"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-009-9351-4","article-title":"The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater","volume":"27","author":"Kim","year":"2010","journal-title":"Med Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt237","article-title":"Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy","volume":"44","author":"Shoji","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.19.7145","article-title":"Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater","volume":"27","author":"Overman","year":"2009","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.953","article-title":"Adjuvant chemotherapy for resected ampulla of Vater carcinoma: retrospective analysis of 646 patients","volume":"53","author":"Kim","year":"2021","journal-title":"Cancer Res Treat"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-333368","article-title":"Mutational signatures define immune and Wnt-associated subtypes of ampullary carcinoma","volume":"74","author":"Zhuravleva","year":"2025","journal-title":"Gut"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30760","article-title":"Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer","volume":"141","author":"Sideras","year":"2017","journal-title":"Int J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33135","article-title":"Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated","volume":"126","author":"Xue","year":"2020","journal-title":"Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1934868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:27:09Z","timestamp":1789730829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1934868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1934868"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1934868","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1934868"}}